Resource impact statement
No significant resource impact is anticipated
NICE has recommended avelumab as an option for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease. Avelumab is currently available for this population through the Cancer Drugs Fund and will become available in routine commissioning as a result of this guidance.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).
This is because the population size is small. It is estimated, based on Cancer Drugs Fund data, that fewer than 100 people will be eligible for treatment with avelumab. This is not expected to change.
Avelumab has a discount that is commercial in confidence.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: